Inhibrx Biosciences announced the departure of Dr. Brendan Eckelman, co-founder and Chief Scientific Officer (CSO), who is leaving to establish a new private biotechnology company. Dr. Carlos Bais, previously Executive Vice President of Translational Sciences, has been appointed as the new CSO.
Additionally, David Matly was promoted to President, in addition to his existing roles as Chief Commercial and Business Development Officer. In his new capacity, Mr. Matly will oversee clinical development and operations, R&D, technical operations, and regulatory affairs, leveraging his experience from a key leadership role in the INBRX-101 asset sale to Sanofi.
Inhibrx also entered into an exclusive license agreement with Dr. Eckelman's new company for certain technologies no longer pursued by Inhibrx. This agreement includes an upfront payment upon initial funding of the new company and potential future development milestones, providing a potential source of non-dilutive funding.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.